RO7284755 is an experimental drug belonging to a new class of immunotherapies called “fusion proteins”. This means that the researchers have “fused” together two drugs to produce a single compound capable of targeting two different molecules with a single medication. This fusion protein works by targeting the molecules PD-1 and IL-2.
Blocking PD-1 helps to prime the body’s immune defences in order to target and destroy cancer cells. This is similar to a drug that is already used to treat Kidney Cancer, called Nivolumab (Opdivo®).
IL-2 is a naturally occurring signalling molecule in the body which helps to increase the intensity of the body’s immune response.
Some patients in this trial may also receive a drug called Atezolizumab. This is a drug that works by targeting a molecule called PDL1. The researchers are interested to see whether delivering this drug in combination produces an even greater anti-cancer effect.
This study will have two treatment groups that will be randomly assigned at the time of enrollment in the trial.
Group 1: RO7284755 alone
Group 2: RO7284755 with Atezolizumab
In order to maximize effectiveness and minimize side effects, difference doses of each drug will be used to determine the optimal dosage of these medications.
There is no control group in the study, so there will be no “placebo”, and all patients will receive treatment.
- All subtypes eligible
- Advanced kidney cancer that cannot be removed by surgery
- No further drug treatments are available or recommended
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentrePrincess Margaret Cancer Center||Principal InvestigatorRoche Pharamceuticals||LocationToronto, ON||Trial StatusNot yet recruiting|